Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
completedphase_2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

NCT05381948
recruitingphase_4

Aflibercept and Bevacizumab for Diabetic Maculopathies

NCT06850571
completedphase_2

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

NCT06099184
recruitingnot_applicable

Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT

NCT06610747

Clinical Trials (4)

Showing 4 of 4 trials
NCT05381948Phase 2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

Completed
NCT06850571Phase 4

Aflibercept and Bevacizumab for Diabetic Maculopathies

Recruiting
NCT06099184Phase 2

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Completed
NCT06610747Not Applicable

Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4